INCR - InterCure Ltd.
After hours:
Chart Events
Inside Bar (Bullish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.0500 |
| Open | 2.0800 |
| Bid | 2.0100 x 1000 |
| Ask | 2.1000 x 900 |
| Day's Range | 2.0600 - 2.1000 |
| 52 Week Range | 1.7300 - 6.6600 |
| Volume | |
| Avg. Volume | 65,696 |
| Market Cap | 99.16M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 13.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GlobeNewswire
InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference
Mr. Rabinovitch is one of the global cannabis senior executives to participateNEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander Rabinovitch, CEO of InterCure, will participate in the Cowen 3rd Annual European Cannabis Conference, taking place May 16th, 2023 in Berlin, Germany. Mr. Rabinovitch will take part in the European Frontier Markets & Israel panel on M
- GlobeNewswire
InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY
Quarterly Annualized Revenue Quarterly Annualized Revenue Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45 million cash and Net current assets of over $72 million NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) is pleased to announce its financial
- GlobeNewswire
InterCure to Be Featured with Mike Tyson in an Exclusive Interview on Fox Business
The Company will be featured on the Claman Countdown show on Monday to discuss its strong 2022 results and recent partnership with Mike TysonNEW YORK and TORONTO and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure'' or the "Company"), the largest and fastest growing medical cannabis company outside of North America, is pleased to announce that its Chairman and former Prime Minister of Israel Mr. Ehud Barak will be featured in an exclusive
- GlobeNewswire
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America announces that on April 24, 2023, it was informed that a lawsuit was filed against the Company in Tel Aviv-Jaffa District Court by minority shareholders of its subsidiary, Cannolam. The lawsuit was filed as part of a conflict between the shareholders and th
- GlobeNewswire
InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel
NEW YORK, TORONTO, and HERZLIYA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading cannabis company outside of North America, announces that on April 23, 2023, it was informed that an application for approval of a class action in Israel was filed against twenty-six defendants, among them the leading cannabis groups in Israel, including the Company and three of its subsidiaries. The subject
- GlobeNewswire
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries
Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson’s premium cannabis brandNEW YORK and TORONTO and HERZLIYA, Israel, April 20, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading cannabis company outside of North America, and TYSON 2.0, a premier cannabis brand known for high-quality cannabis
- GlobeNewswire
InterCure Reschedules 2022 Full Year Results Conference Call
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen
- GlobeNewswire
InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
InterCure 2020-2022 Financials InterCure 2020-2022 Financials Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) is pleased
- GlobeNewswire
InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) the biggest and most profitable cannabis company outside of north America, announced today that it has filed a lawsuit against Cann Pharmaceuticals Ltd. (dba “Better”), a company with which it had previously sought to merge, to recover funds loaned and invested in the course of their dealings in connection with the merger
- GlobeNewswire
InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)
NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that, further to the merger agreement with Cann Pharmaceutical Ltd. (“Better”) dated as of February 13, 2022, pursuant to which and subject to its terms, InterCure was to acquire 100% of the issued and outstanding shares of Better (the “Agreement”), and further to the Company’s press release dated November 23,
- GlobeNewswire
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"
Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, Inc. to license, manufacture and distribute the Florida-based cannabis brand ”Binske”NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the largest and fastest growing medical cannabis company outside of North America, today announced that it has entered into a
- GlobeNewswire
InterCure to Participate in Cowen 5th Annual Cannabis Conference
Mr. Rabinovitch is one of the global cannabis senior executives to participateNEW YORK and TORONTO and HERZLIYA, Israel, Dec. 08, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will participate in Cowen 5th Annual Cannabis Conference, taking place December 8th, 2022. Mr. Rabinovitch will take part in the industry leaders panel on Thursday, December 8th, 202
- GlobeNewswire
InterCure Announces the Withdrawal of a Class Action Lawsuit against it
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce the withdrawal of a class action lawsuit against it (the “Regenera Lawsuit”). The Regenera Lawsuit was described in the Company’s press release dated May 26, 2020 and in the Company's most recent Annual Report and Annual Information Form and it was primarily concerning a motion to certify, as a cl
- GlobeNewswire
Update regarding Better Transaction
NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 23, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is hereby providing an update that further to the announcement from February 16, 2022, regarding the signed agreement with Cann Pharmaceutical Ltd. (“Better”) to acquire 100% of Better’s shares (the “Transaction”), which as set out in the Company’s reports is subject to certain closing conditions, as of this date, there
- GlobeNewswire
Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
Organigram to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple yearsTORONTO and HERZILA, Israel, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”), a leading Canadian licensed producer of cannabis, and Canndoc Ltd. (“Canndoc”), a subsidiary of InterCure Ltd. (NASDAQ: INCR) (TSX:INCR.U) (TASE:INCR) (dba Canndoc) Israel’s largest and most established pharmaceutical cannabis producer,
- GlobeNewswire
CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth
Rapid Revenue and EBITDA Growth Rapid Revenue and EBITDA Growth NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, by InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR), please note that multiple numbers were incorrect and have been updated. The corrected release follows: Eleventh consecutive quarter of sequential profitable revenue growth Annualized revenue run rate of $155 million Adjusted EBITDA1 run ra
- GlobeNewswire
InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth
Eleventh consecutive quarter of sequential profitable revenue growth Annualized revenue run rate of $155 million Adjusted EBITDA1 run rate of $36 million Achieved Run Rate Net Profit of 12$ million Strong balance sheet with $93 million cash supporting future profitable growth NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) is pleased to announce its financial and ope
- GlobeNewswire
InterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoY
Estimated revenue reaches CAD$39 million1 (a record of over NIS 100 million): Eleventh consecutive quarter of profitable growth with revenue growth expected to continue in Q4 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) today announced record preliminary financial results for the Third quarter of 2022. All amounts are expressed in Canadian dollars ($) or New Israeli Shekel
- GlobeNewswire
Intercure Ltd. Announces Voting Results from its Annual and Special Meeting of Shareholders
HERZLIYA, Israel, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Intercure Ltd. (the “Company”) announces today the results of the Annual and Special General Meeting of shareholders of the Company, held on Thursday, September 15, 2022, in Bnei Brak, Israel (the “Meeting”). At the Meeting, all of the proposals set forth in the Company’s management information circular dated August 10, 2022 (the “Circular”) were approved by the required majority of the shareholders. Each of the four nominees listed in the man
- GlobeNewswire
InterCure Reports Record Breaking Second Quarter Financial Results
Rapid Revenue and EBITDA Growth Rapid Revenue and EBITDA Growth by Half Year CAD millions Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expect
- GlobeNewswire
InterCure to Release its Q2 2022 Results and Hold a Conference Call
Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ETNEW YORK and TORONTO and HERZLIYA, Israel, Aug. 11, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it plans to release financial results for the second quarter of 2022 after market close on Monday, August 15, 2022. InterCure executives will host a live conference call and audio webcast to discuss these results on Tuesday, August 1
- GlobeNewswire
InterCure Reports Record Preliminary 2022 Second Quarter Revenue – More Than Double YoY and 9% QoQ Growth
Estimated revenue reaches CAD$36 million 1(a record NIS 95 million) Anticipates continued increases in EBITDA Revenue growth expected to continue in Q3 and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, July 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) today announced record preliminary financial results for the second quarter of 2022. All amounts are expressed in Canadian dollars ($) or New Israeli Shekels (NIS)
- GlobeNewswire
Clever Leaves Announces First Export to Israeli Partner InterCure
Clever Leaves has officially entered into Israel’s flower market with the first commercial high-quality THC flower export from its GACP certified cultivation facility in PortugalBOCA RATON, Fla., July 18, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the first commercial export to Israel of high THC Flower for medical use fr
- GlobeNewswire
InterCure and Cookies Launch Flagship Retail Location in Vienna, Austria
Cookies Store Vienna InterCure's Cookies branded retail location in Vienna NEW YORK and TORONTO and HERZLIYA, Israel, June 21, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) announced today the successful opening of the first flagship Cookies store in Austria, located in the Neubau district of Vienna. The flagship location offers Cookies' unique CBD menu, available for the first time in Europe, as well as clothing and life-style p
- GlobeNewswire
InterCure and Cookies Successfully Launch Flagship Pharmacy in Be'er Sheva, Israel
Cookies Be'er Sheva is the largest medical cannabis dedicated pharmacy in Israel Cookies Pharmacy in Be'er Sheva Cookies Pharmacy in Be'er Sheva NEW YORK and TORONTO and HERZLIYA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure" or the “Company”) announced today the grand opening of its flagship Cookies pharmacy in Be'er Sheva, the largest city in Israel's southern region, known as the capital of the Negev. The pharmacy is located in
